Fluticasone propionate

also known as Flixotide · Seretide · Advair Diskus · Flonase · FLOVENT · fluticasone · Flovent Diskus · Advair · +27 more

Other / unclassified

Developed for: asthma · chronic obstructive pulmonary disease · allergic rhinitis · eosinophilic esophagitis · seasonal allergic rhinitis · atopic eczema · blepharitis · childhood onset asthma
+27 more
· chronic asthma · chronic rhinosinusitis · nasal cavity polyp · perennial allergic rhinitis · transplant-related bronchiolitis obliterans · allergic contact dermatitis · bronchiolitis · bronchogenic carcinoma · COVID-19 · depressive disorder · environmental induced asthma · exercise-induced bronchoconstriction · hypersensitivity reaction disease · laryngeal disorder · lung disorder · osteoarthritis, knee · polyp of vocal cord · rhinitis · skin disorder · vitiligo · allergic asthma · bronchitis · conjunctivitis · eustachian tube disorder · intermittent asthma · lower respiratory tract disorder · obstructive lung disease
Investigated by: GlaxoSmithKline · Teva Branded Pharmaceutical Products R&D, Inc. · Dey · Pfizer · Children's Hospital Medical Center, Cincinnati · Ellodi Pharmaceuticals, LP
+108 more
· National Heart, Lung, and Blood Institute (NHLBI) · SkyePharma AG · Boehringer Ingelheim · Milton S. Hershey Medical Center · Optinose US Inc. · Teva Pharmaceuticals USA · Abbott · Actavis Inc. · Brian J Lipworth · Fraunhofer-Institute of Toxicology and Experimental Medicine · Mundipharma Research Limited · National Institute of Allergy and Infectious Diseases (NIAID) · Nicox Ophthalmics, Inc. · Novartis Pharmaceuticals · The Netherlands Asthma Foundation · University of Chicago · University of Dundee · University of Florida · University of Miami · Academisch Ziekenhuis Groningen · Adare Pharmaceuticals, Inc. · Allergy Centre Vienna West · Amsterdam UMC, location VUmc · Assaf-Harofeh Medical Center · Assistance Publique - Hôpitaux de Paris · AstraZeneca · Bausch & Lomb Incorporated · Bayer · Becro Ltd. · Benha University · Chiesi Farmaceutici S.p.A. · Childhood Asthma Research and Education Network · Children's Hospital of Fudan University · Cipla Ltd. · Creighton University · Dutch Health Care Insurance Board · Egalet Ltd · Eupraxia Pharmaceuticals Inc. · Far Eastern Memorial Hospital · Fougera Pharmaceuticals Inc. · Glenmark Pharmaceuticals Ltd. India · Guy's and St Thomas' NHS Foundation Trust · Harvard School of Public Health (HSPH) · Henan University of Traditional Chinese Medicine · Imperial College London · Inje University · Johns Hopkins University · Joseph Dohar, MD · Kari Nadeau, MD, PhD · Kindeva Drug Delivery · King Edward Medical University · King's College London · Leiden University Medical Center · Libbs Farmacêutica LTDA · M.D. Anderson Cancer Center · Marc Rothenberg · Marc Rothenberg, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre · Meda Pharmaceuticals · Medical University of Vienna · Mylan Pharma UK Ltd. · National Cancer Institute (NCI) · National Center for Advancing Translational Sciences (NCATS) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institutes of Health (NIH) · National Jewish Health · National Natural Science Foundation of China · Neothetics, Inc · Netherlands Institute for Pigment Disorders · Netherlands Organisation for Scientific Research · Office of Rare Diseases (ORD) · Organon and Co · Oriel Therapeutics · Orion Corporation, Orion Pharma · all 114 on the full record

Regulatory milestones approvals, filings & regulatory actions · 13 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	XHANCE	—	2024-03-15	fda.gov ↗
Label expansion	US (FDA)	ARMONAIR RESPICLICK	—	2021-07-09	fda.gov ↗
Approved	EU (EMA)	Aerivio Spiromax	—	2016-08-18	europa.eu ↗
Label expansions (4)	US (FDA)	CUTIVATE	—	1997-04-25 – 2015-01-16	fda.gov ↗
Label expansion	US (FDA)	FLOVENT HFA	—	2006-02-28	fda.gov ↗
Label expansions (4)	US (FDA)	FLONASE	—	1997-10-31 – 2003-05-01	fda.gov ↗
Approved	US (FDA)	CUTIVATE	—	1990-12-14	fda.gov ↗

Trials 187 · started per year

today

US approved 1990

EU approved 2016

199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT02826343	May 2016 → Jun 2018	chronic obstructive pulmonary disease	University of Virginia	Completed	No outcome recorded
Phase 0	NCT03594565	Mar 2016 → Jun 2017	hypersensitivity reaction disease, type 1 diabetes mellitus	Assaf-Harofeh Medical Center	Completed	No outcome recorded
Phase 123 trials
Phase 1	NCT06290102	May → Oct 2024	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT03040596	Mar 2017 → Jan 2019	polyp of vocal cord	Joseph Dohar, MD	Terminated	No outcome recorded
Phase 1	NCT02680561	Apr → Jun 2016	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT02609126	Apr 2016 → Dec 2017	osteoarthritis, knee	Eupraxia Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 1	NCT02437604	May → Jul 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 1	NCT02218762	Oct 2014 → Jun 2015	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 1	NCT02260492	Sep 2014 → May 2015	asthma	Oriel Therapeutics	Completed	No outcome recorded
Phase 1	NCT02232087	Jul → Oct 2014	—	Kindeva Drug Delivery	Completed	No outcome recorded
Phase 1	NCT01890863	Aug → Sep 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01564199	Apr → Jun 2012	—	Orion Corporation, Orion Pharma	Completed	No outcome recorded
Phase 1	NCT01540708	Jan → Sep 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01449799	Jul → Sep 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01364519	Jul 2011 → Jan 2012	chronic obstructive pulmonary disease	Pfizer	Completed	No outcome recorded
Phase 1	NCT01181700	Oct 2010 → Jan 2011	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT01064726	Oct 2009 → Apr 2010	allergic rhinitis	Pfizer	Completed	No outcome recorded
Phase 1	NCT00867282	Jun → Jul 2009	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT00862667	May → Jun 2009	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT00657774	Apr → Sep 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 1	NCT01365611	Feb → May 2007	—	Egalet Ltd	Completed	No outcome recorded
Phase 1	NCT00370097	Aug 2006 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00348361	Apr 2005 → ?	allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00364442	Jan → Apr 2005	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00280358	? → Dec 2005	—	Dey	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT01494610	Oct 2010 → Jun 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 225 trials
Phase 2	NCT03742414	Jun 2021 → May 2028 expected	atopic eczema	Kari Nadeau, MD, PhD	Active not recruiting	No outcome recorded
Phase 2	NCT04675242	Dec 2020 → Jun 2021	blepharitis	Nicox Ophthalmics, Inc.	Completed	No outcome recorded
Phase 2	NCT06051786	Aug 2020 → Jul 2021	allergic rhinitis	Synmosa Biopharma Corp.	Completed	No outcome recorded
Phase 2	NCT03926026	Mar → Oct 2019	blepharitis	Nicox Ophthalmics, Inc.	Completed	No outcome recorded
Phase 2	NCT04179461	Mar 2018 → Oct 2019	childhood onset asthma	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 2	NCT03191864	Jun 2017 → Jan 2019	eosinophilic esophagitis	Adare Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT02991859	Feb 2017 → Dec 2018	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01576718	Apr 2012 → Jul 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT01516086	Mar 2012 → Nov 2013	asthma	Dey	Completed	No outcome recorded
Phase 2	NCT01516073	Mar 2012 → Nov 2013	asthma	Dey	Completed	No outcome recorded
Phase 2	NCT01479621	Jan 2012 → Jul 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT01578278	Dec 2011 → Aug 2012	seasonal allergic rhinitis	Bausch & Lomb Incorporated	Completed	No outcome recorded
Phase 2	NCT01712451	Aug 2011 → Oct 2012	—	Neothetics, Inc	Completed	No outcome recorded
Phase 2	NCT01307462	Jun 2011 → Sep 2014	transplant-related bronchiolitis obliterans	Stephanie Lee	Completed	No outcome recorded
Phase 2	NCT01424397	Apr → Jul 2011	rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01253603	Nov 2010 → Sep 2011	chronic asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01168310	Aug 2010	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT01007721	Oct 2009 → Apr 2010	asthma, seasonal allergic rhinitis	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00656916	Mar 2008 → Dec 2010	bronchiolitis	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00612820	Jan → May 2008	seasonal allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00426283	Jan 2007 → Dec 2011	eosinophilic esophagitis	Marc Rothenberg, MD	Completed	No outcome recorded
Phase 2	NCT00403286	Nov 2006 → May 2007	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT00325169	Dec 2005 → Aug 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00400855	Jan → Aug 2005	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00407264	Feb 2002 → Dec 2005	bronchogenic carcinoma	Amsterdam UMC, location VUmc	Completed	No outcome recorded

Phase 2/34 trials
Phase 2/3	NCT05535738	Nov 2022 → Jan 2027 expected	allergic contact dermatitis	Wei-Che Ko	Active not recruiting	No outcome recorded
Phase 2/3	NCT05054322	Sep 2021 → Jan 2022	COVID-19	University of Medicine and Pharmacy at Ho Chi Minh City	Unknown	No outcome recorded
Phase 2/3	NCT02778867	May 2016 → Apr 2019	eosinophilic esophagitis	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 2/3	NCT02610816	Mar 2016 → May 2018	eosinophilic esophagitis	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 354 trials
Phase 3	NCT06664619	Dec 2024 → Sep 2026 expected	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Recruiting	No outcome recorded
Phase 3	NCT06052267	Aug 2023 → Oct 2026 expected	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Active not recruiting	No outcome recorded
Phase 3	NCT05634746	Dec 2022 → Aug 2024	eosinophilic esophagitis	Ellodi Pharmaceuticals, LP	Completed	No outcome recorded
Phase 3	NCT05363202	Apr 2022 → May 2024	asthma	Glenmark Pharmaceuticals Ltd. India	Unknown	No outcome recorded
Phase 3	NCT05083312	Sep 2021 → Sep 2022	eosinophilic esophagitis	Ellodi Pharmaceuticals, LP	Completed	No outcome recorded
Phase 3	NCT04655508	May 2021 → Sep 2023	disease related to hematopoietic stem cell transplant, transplant-related bronchiolitis obliterans	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 3	NCT04665895	Dec 2020 → Aug 2021	asthma	Respirent Pharmaceuticals Co Ltd.	Completed	No outcome recorded
Phase 3	NCT04281108	Jan 2020 → May 2022	eosinophilic esophagitis	Ellodi Pharmaceuticals, LP	Completed	No outcome recorded
Phase 3	NCT03879837	Mar 2019 → May 2021	asthma	Actavis Inc.	Completed	No outcome recorded
Phase 3	NCT03394989	Oct 2018 → Dec 2019	asthma	Cipla Ltd.	Completed	No outcome recorded
Phase 3	NCT03591068	Jun 2018 → Feb 2019	nasal cavity polyp	Optinose US Inc.	Completed	No outcome recorded
Phase 3	NCT03169504	May 2017 → May 2018	chronic obstructive pulmonary disease	Henan University of Traditional Chinese Medicine	Unknown	No outcome recorded
Phase 3	NCT02980133	Dec 2016 → Apr 2019	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02924688	Oct 2016 → Feb 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02496715	Sep 2015 → Oct 2016	asthma	Actavis Inc.	Withdrawn	No outcome recorded
Phase 3	NCT02301975	Mar 2015 → Nov 2016	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02523820	Jan 2015 → May 2016	laryngeal disorder	Ramathibodi Hospital	Completed	No outcome recorded
Phase 3	NCT02245672	Oct 2014 → Jul 2015	asthma	Mylan Pharma UK Ltd.	Completed	No outcome recorded
Phase 3	NCT02249663	Aug 2014 → Feb 2015	seasonal allergic rhinitis	Teva Pharmaceuticals USA	Unknown	No outcome recorded
Phase 3	NCT04332978	Jul 2014 → Apr 2020	perennial allergic rhinitis	Libbs Farmacêutica LTDA	Completed	No outcome recorded
Phase 3	NCT02175771	Jul 2014 → Jul 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02139644	Jun 2014 → Sep 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02141854	Jun 2014 → Sep 2015	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 3	NCT02094937	Mar 2014 → Aug 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02246920	Mar → Jul 2014	seasonal allergic rhinitis	Teva Pharmaceuticals USA	Terminated	No outcome recorded
Phase 3	NCT01967173	Feb 2014 → Jul 2017	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT01978145	Nov 2013 → Apr 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01978119	Nov 2013 → Jan 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01946620	Oct 2013 → Apr 2016	chronic obstructive pulmonary disease	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT01623310	Sep 2013 → Aug 2015	nasal cavity polyp	Optinose US Inc.	Completed	No outcome recorded
Phase 3	NCT01623323	Sep 2013 → Mar 2015	chronic rhinosinusitis	Optinose US Inc.	Completed	No outcome recorded
Phase 3	NCT01606306	Feb 2013 → Apr 2015	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT01817790	Dec 2012 → Feb 2013	seasonal allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01687296	Nov 2012 → Jun 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01687283	Sep 2012 → Nov 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00883168	Apr → Jul 2009	seasonal allergic rhinitis	Meda Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00747318	Sep 2008 → May 2010	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 3	NCT00395304	Mar 2007 → Dec 2011	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT00475813	Mar 2007 → Feb 2008	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT00449046	Mar → Nov 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00441441	Feb 2007 → Jan 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00411372	Nov 2006 → ?	chronic obstructive pulmonary disease	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT00394199	Jun 2006 → Feb 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 3	NCT00394121	Mar 2006 → Jul 2007	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 3	NCT00328718	Oct 2005 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00269126	Feb → Aug 2005	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00394368	Nov 2004 → Sep 2005	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT00549146	Nov 2003 → Apr 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00266578	Oct 2002 → Nov 2006	eosinophilic esophagitis	Marc Rothenberg	Completed	No outcome recorded
Phase 3	NCT00268177	Oct 2002 → Dec 2003	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00920959	Nov 2001 → Jan 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00489346	Oct 2001 → Jun 2002	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00268216	Sep 2000 → Nov 2005	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00158834	Nov 1999 → ?	asthma	GlaxoSmithKline	Completed	No outcome recorded

Phase 467 trials
Phase 4	NCT07675252	Aug 2026 → May 2027 expected	—	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Not yet recruiting	No outcome recorded
Phase 4	NCT07664527	Jul 2026 → Apr 2027 expected	asthma	University of Wisconsin, Madison	Not yet recruiting	No outcome recorded
Phase 4	NCT06858423	Aug 2023 → Mar 2024	allergic rhinitis	Benha University	Completed	No outcome recorded
Phase 4	NCT07415278	Dec 2022 → Oct 2023 overdue	allergic rhinitis	Pamukkale University	Active not recruiting	No outcome recorded
Phase 4	NCT05444543	Nov 2021 → Oct 2023	eosinophilic esophagitis	University Hospitals Cleveland Medical Center	Completed	No outcome recorded
Phase 4	NCT04527016	Oct 2021 → Jun 2023	childhood onset asthma	Children's Hospital of Fudan University	Completed	No outcome recorded
Phase 4	NCT05080322	Sep 2021 → Dec 2024	allergic rhinitis	Zheng Liu ENT	Unknown	No outcome recorded
Phase 4	NCT04677959	Feb 2021 → Mar 2022	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 4	NCT04601324	Dec 2020 → Jun 2021	allergic rhinitis	St. Paul's Sinus Centre	Withdrawn	No outcome recorded
Phase 4	NCT04957927	Dec 2020 → Sep 2021	allergic rhinitis	Usama Azhar	Unknown	No outcome recorded
Phase 4	NCT03443843	Feb → May 2018	allergic rhinitis	Bayer	Completed	No outcome recorded
Phase 4	NCT03219866	Oct 2017 → Apr 2020	chronic obstructive pulmonary disease	Wake Forest University Health Sciences	Terminated	No outcome recorded
Phase 4	NCT02813200	Jan 2017 → Feb 2019	chronic obstructive pulmonary disease	University Hospital, Bordeaux	Completed	No outcome recorded
Phase 4	NCT02730351	May 2016 → Feb 2017	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02402465	Feb 2015 → Mar 2018	allergic rhinitis	University of Chicago	Completed	No outcome recorded
Phase 4	NCT02113436	May 2014 → Jun 2016	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01915914	Dec 2013 → Feb 2015	skin disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01916226	Aug → Oct 2013	allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01845025	May 2013 → May 2016	chronic asthma	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT01554488	Mar 2013 → Feb 2016	asthma, chronic obstructive pulmonary disease, obstructive sleep apnea syndrome	VA Office of Research and Development	Terminated	No outcome recorded
Phase 4	NCT01762800	Feb 2013 → Sep 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01607398	May 2012 → Jul 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01124422	Jul 2010 → May 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00974805	Feb 2010 → Feb 2012	chronic obstructive pulmonary disease	University of Southampton	Completed	No outcome recorded
Phase 4	NCT00984659	Oct 2009 → Jul 2010	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00974246	Oct 2009 → Jul 2011	chronic obstructive pulmonary disease, depressive disorder	Valley Medical Research	Completed	No outcome recorded
Phase 4	NCT01647646	Mar 2009 → Feb 2011	asthma	Far Eastern Memorial Hospital	Completed	No outcome recorded
Phase 4	NCT00975195	Feb 2009 → Jul 2013	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00784550	Dec 2008 → Dec 2009	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00692978	Aug 2008 → Jul 2011	asthma	Imperial College London	Completed	No outcome recorded
Phase 4	NCT02136875	Jul 2008 → Aug 2010	chronic obstructive pulmonary disease	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 4	NCT00487032	May 2008 → May 2009	allergic rhinitis	Brian J Lipworth	Completed	No outcome recorded
Phase 4	NCT00633217	Mar 2008 → Feb 2009	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00848965	Oct 2007 → Jan 2008	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00517634	Aug 2007 → Jul 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00546000	Jul 2007 → Dec 2008	atopic eczema	Fougera Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 4	NCT00461812	Apr 2007 → Jan 2010	asthma	Johns Hopkins University	Terminated	No outcome recorded
Phase 4	NCT00461500	Mar → Dec 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00712335	Feb 2007 → May 2011	environmental induced asthma	Inje University	Completed	No outcome recorded
Phase 4	NCT00346749	Dec 2006 → Jul 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Terminated	No outcome recorded
Phase 4	NCT00903227	Dec 2006 → Aug 2008	allergic rhinitis, asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT00995475	Oct 2006 → Nov 2008	chronic obstructive pulmonary disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT00400608	Oct 2006 → Feb 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00358358	Mar 2006 → Feb 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00353873	Nov 2005 → Oct 2006	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00291382	Nov 2005 → Jul 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00296530	Sep 2005 → Jul 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00197106	Jun 2005 → Oct 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00455923	May 2005 → Jul 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00115492	Dec 2004 → Jun 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00102765	Nov 2004 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00144911	Oct 2004 → Dec 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00102882	Oct 2004 → Jan 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00355342	Apr 2004 → Sep 2007	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00118716	Dec 2003 → Apr 2006	exercise-induced bronchoconstriction	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00239421	Nov 2003 → Sep 2004	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00361959	Jun 2003 → Feb 2006	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00307970	Apr → Sep 2003	asthma	University of Florida	Completed	No outcome recorded
Phase 4	NCT00308932	Feb 2003 → Apr 2004	asthma	University of Florida	Completed	No outcome recorded
Phase 4	NCT00169546	Jan 2003 → Dec 2005	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00370591	Dec 2002 → Apr 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00479739	Nov 2002 → Jul 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00453778	Nov 2002 → May 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00158847	Apr 2000 → May 2005	chronic obstructive pulmonary disease	Leiden University Medical Center	Terminated	No outcome recorded
Phase 4	NCT00184977	Dec 1998 → Jan 2003	chronic bronchitis	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT01657097	Feb → Apr 1997	allergic rhinitis, asthma	University of Aarhus	Completed	No outcome recorded
Phase 4	NCT00846326	—	allergic rhinitis	Brian J Lipworth	Withdrawn	No outcome recorded

Phase not applicable10 trials
—	NCT03524066	Apr → Dec 2018	—	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
—	NCT02290717	May → Nov 2015	vitiligo	Netherlands Institute for Pigment Disorders	Withdrawn	No outcome recorded
—	NCT02182492	Jan 2014 → Dec 2015	chronic rhinosinusitis	Zheng Liu	Completed	No outcome recorded
—	NCT02141633	Apr 2013 → Jun 2015	—	University of Miami	Completed	No outcome recorded
—	NCT01400568	Aug 2011 → Jan 2012	—	Fraunhofer-Institute of Toxicology and Experimental Medicine	Completed	No outcome recorded
—	NCT01213693	May 2009 → May 2013	chronic obstructive pulmonary disease	Università degli Studi di Ferrara	Completed	No outcome recorded
—	NCT01231230	May 2007 → Dec 2009	asthma	University of Miami	Completed	No outcome recorded
—	NCT00385463	Apr 2006 → Apr 2007	asthma, seasonal allergic rhinitis	Creighton University	Withdrawn	No outcome recorded
—	NCT00272441	Jan 2001 → Sep 2004	asthma, lung disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
—	NCT00755066	—	seasonal allergic rhinitis	Medical University of Vienna	Completed	No outcome recorded
Phase not stated1 trial
—	NCT05095116	—	eosinophilic esophagitis	Ellodi Pharmaceuticals, LP	No longer available	No outcome recorded

Also used as a comparator or background therapy in 157 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 17 trials
Phase 1	NCT03112577 Comparator	Jun 2017 → Mar 2019	allergic asthma	Regeneron Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT01966692 Comparator	Nov 2016 → Jan 2018	asthma	University of Florida	Completed	No outcome recorded
Phase 1	NCT02474017 Background	May → Jun 2015	asthma, chronic obstructive pulmonary disease	Mylan Pharma UK Ltd.	Completed	No outcome recorded
Phase 1	NCT02266927 Comparator	Sep 2014 → Mar 2015	asthma	Optinose US Inc.	Completed	No outcome recorded
Phase 1	NCT00877539 Comparator	Jun → Dec 2009	asthma	Pfizer	Completed	No outcome recorded
Phase 1	NCT00869596 Comparator	Mar → Sep 2009	lower respiratory tract disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00404586 Background	Sep 2006 → Jan 2007	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT05689983 Comparator	Apr 2022 → Dec 2025 overdue	childhood onset asthma	Washington University School of Medicine	Active not recruiting	No outcome recorded
Phase 231 trials
Phase 2	NCT07324707 Comparator	Oct 2025 → Mar 2026 overdue	asthma	Anhui Palo Alto Pharmaceuticals, Inc.	Recruiting	No outcome recorded
Phase 2	NCT05275686 Comparator	Apr 2022 → Jun 2027 expected	eustachian tube disorder	Cedars-Sinai Medical Center	Recruiting	No outcome recorded
Phase 2	NCT03207243 Background	Sep 2017 → Feb 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02874144 Background	Jun 2016 → Jan 2020	nasal cavity polyp	Northwestern University	Completed	No outcome recorded
Phase 2	NCT02573233 Background	Jan 2016 → Jan 2018	asthma	Sanofi	Completed	No outcome recorded
Phase 2	NCT02251379 Background	Oct 2014 → Nov 2018	asthma	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT02569437 Background	Sep 2014 → Aug 2016	polyp	Icahn School of Medicine at Mount Sinai	Terminated	No outcome recorded
Phase 2	NCT02740543 Comparator	Dec 2013 → Oct 2019	asthma	NYU Langone Health	Completed	No outcome recorded
Phase 2	NCT01772368 Comparator	Jan → Jun 2013	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT01738087 Comparator	Nov 2012 → Jan 2013	asthma	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 2	NCT01573767 Comparator	Apr 2012 → Apr 2014	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01563029 Comparator	Mar 2012 → Sep 2014	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01397162 Comparator	Jul → Dec 2011	asthma	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 2	NCT01400906 Comparator	Jul 2011 → Dec 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01396278 Comparator	Jul → Dec 2011	asthma	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 2	NCT01397201 Comparator	Jul → Dec 2011	asthma	Boehringer Ingelheim	Terminated	No outcome recorded
Phase 2	NCT01260753 Comparator	Dec 2010 → Mar 2011	seasonal allergic rhinitis	Palau Pharma S.L.U.	Completed	No outcome recorded
Phase 2	NCT01248975 Background	Dec 2010 → Oct 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01156792 Background	Sep 2010 → Oct 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01147744 Comparator	Jun 2010 → Oct 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01092143 Comparator	Mar 2010 → Mar 2011	asthma	Boehringer Ingelheim	Completed	No outcome recorded
Phase 2	NCT00995800 Comparator	Oct 2009 → Jul 2010	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 2	NCT00927758 Comparator	Jun → Dec 2009	asthma	Sandoz	Completed	No outcome recorded
Phase 2	NCT00843193 Background	Dec 2008 → Jul 2010	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00814216 Comparator	Dec 2008 → Oct 2009	asthma	Novartis	Completed	No outcome recorded
Phase 2	NCT00774761 Comparator	Nov 2008 → Apr 2009	chronic obstructive pulmonary disease	Dey	Completed	No outcome recorded
Phase 2	NCT00734292 Comparator	Sep 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 2	NCT00642148 Comparator	Feb 2008 → Jul 2009	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00241631 Comparator	Apr 2006 → Aug 2007	chronic obstructive pulmonary disease	Imperial College London	Completed	No outcome recorded
Phase 2	NCT00400998 Comparator	Mar → Nov 2006	seasonal allergic rhinitis	Research Consult GmbH	Completed	No outcome recorded
Phase 2	NCT00830102 Comparator	Oct 2004 → Jan 2005	asthma	SkyePharma AG	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT04242368 Background	Jul 2020 → Jul 2021	chronic rhinosinusitis	Stanford University	Withdrawn	No outcome recorded
Phase 357 trials
Phase 3	NCT07582549 Comparator	Dec 2025 → Dec 2027 expected	—	Tampere University Hospital	Recruiting	No outcome recorded
Phase 3	NCT06850805 Comparator	Jul 2025 → Mar 2028 expected	chronic rhinosinusitis	Optinose US Inc.	Recruiting	No outcome recorded
Phase 3	NCT05545072 Background	Oct 2023 → Jul 2024	chronic rhinosinusitis	Emory University	Terminated	No outcome recorded
Phase 3	NCT03756883 Comparator	Dec 2018 → Oct 2019	asthma	Actavis Inc.	Completed	No outcome recorded
Phase 3	NCT03676413 Comparator	Oct 2018 → Aug 2019	asthma	Respirent Pharmaceuticals Co Ltd.	Completed	No outcome recorded
Phase 3	NCT03562923 Comparator	Oct 2018 → May 2019	asthma	Amneal Ireland Limited	Unknown	No outcome recorded
Phase 3	NCT03599791 Comparator	Jun 2018 → Sep 2019	allergic rhinitis	MEDA Pharma GmbH & Co. KG	Completed	No outcome recorded
Phase 3	NCT03468790 Background	May 2018 → Jan 2021	allergic asthma	Shanghai Biomabs Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03461627 Comparator	Apr 2017 → Oct 2018	asthma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT02554786 Comparator	Dec 2015 → Nov 2018	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02571777 Comparator	Dec 2015 → Jun 2019	asthma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02446418 Comparator	Jul 2015 → Jul 2017	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02230696 Comparator	Aug 2014 → Feb 2015	seasonal allergic rhinitis	Padagis LLC	Completed	No outcome recorded
Phase 3	NCT02066129 Comparator	Jul 2014 → Apr 2017	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT01622569 Comparator	Nov 2013 → Aug 2015	nasal cavity polyp	Optinose US Inc.	Completed	No outcome recorded
Phase 3	NCT01624662 Comparator	Oct 2013 → May 2015	nasal cavity polyp	Optinose US Inc.	Completed	No outcome recorded
Phase 3	NCT01969721 Comparator	Oct 2013 → Jan 2015	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01908140 Comparator	Sep 2013 → Aug 2014	chronic obstructive pulmonary disease	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT01879410 Comparator	Jun 2013 → Jan 2014	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01822899 Comparator	Apr → Oct 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01817764 Comparator	Mar → Oct 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01794741 Comparator	Feb → Nov 2013	allergic rhinitis	Meda Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01772134 Background	Jan → Jul 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01772147 Comparator	Jan → Aug 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01706328 Comparator	Oct 2012 → Jun 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01513460 Background	Apr 2012 → Dec 2013	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01511367 Comparator	Mar 2012 → Sep 2013	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT01498653 Comparator	Jan 2012 → Feb 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01435902 Comparator	Jan → Aug 2012	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT01436110 Comparator	Sep 2011 → Sep 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01323634 Comparator	Mar → Dec 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01323621 Comparator	Mar 2011 → Jan 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01274325 Comparator	Feb 2011 → Apr 2013	asthma	Mahidol University	Completed	No outcome recorded
Phase 3	NCT01159912 Comparator	Jun 2010 → Jan 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01134042 Comparator	Jun 2010 → Oct 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01147848 Comparator	Jun 2010 → Jul 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01018186 Comparator	Oct 2009 → May 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00734318 Comparator	Sep 2008 → Jun 2009	asthma	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT00740792 Comparator	Aug → Nov 2008	seasonal allergic rhinitis	Meda Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00651118 Comparator	Mar → Jun 2008	seasonal allergic rhinitis	Meda Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00649025 Comparator	Mar → Oct 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 3	NCT00660517 Comparator	Dec 2007 → Feb 2008	seasonal allergic rhinitis	Meda Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00562159 Background	Nov 2007 → Sep 2009	allergic disease, conjunctivitis, rhinitis	ALK-Abelló A/S	Completed	No outcome recorded
Phase 3	NCT00540839 Comparator	Nov 2007 → Mar 2008	asthma	Organon and Co	Withdrawn	No outcome recorded
Phase 3	NCT00424008 Comparator	Apr 2007 → Nov 2008	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00448435 Comparator	Apr 2007 → Jan 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00398476 Comparator	Dec 2006	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00393991 Comparator	Jul 2006 → Apr 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 3	NCT00318708 Background	Jun 2006 → Apr 2009	asthma	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT00393952 Comparator	Jun 2006 → Apr 2008	asthma	SkyePharma AG	Completed	No outcome recorded
Phase 3	NCT00379288 Comparator	Jun 2006 → Nov 2007	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00284856 Comparator	May 2006 → Apr 2010	asthma	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00628758 Background	Dec 2005 → Sep 2008	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00783224 Comparator	Sep → Nov 2005	perennial allergic rhinitis	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00646594 Comparator	Nov 2003 → Jan 2005	asthma	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00641680 Comparator	Apr → Jul 2003	seasonal allergic rhinitis	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT03882047 Comparator	Aug → Sep 1994	seasonal allergic rhinitis	Organon and Co	Completed	No outcome recorded

Phase 447 trials
Phase 4	NCT07294326 Comparator	Jan → Oct 2026 expected	allergic rhinitis	China-Japan Union Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT05314621 Comparator	Dec 2021 → Jul 2022	conjunctivitis	Andover Research Eye Institute	Completed	No outcome recorded
Phase 4	NCT04953741 Comparator	Aug 2021 → Aug 2022	childhood onset asthma	Xijing Hospital	Unknown	No outcome recorded
Phase 4	NCT03240575 Comparator	Aug 2017 → Apr 2019	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT03055988 Comparator	Mar 2017 → Mar 2018	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT02972476 Comparator	Dec 2016 → Jul 2019	chronic obstructive pulmonary disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT03199976 Comparator	Apr 2016 → Nov 2020	asthma, bronchitis, obstructive lung disease	Helsinki University Central Hospital	Terminated	No outcome recorded
Phase 4	NCT02476825 Comparator	Jan 2016 → Oct 2026 expected	—	University Hospitals, Leicester	Active not recruiting	No outcome recorded
Phase 4	NCT03110874 Background	Oct 2015 → Sep 2016	asthma	Hanmi Pharmaceutical Company Limited	Completed	No outcome recorded
Phase 4	NCT02257372 Background	Sep 2014 → Mar 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT02338362 Comparator	Sep 2014 → Feb 2015	ocular hypertension, open-angle glaucoma	University Health Network, Toronto	Completed	No outcome recorded
Phase 4	NCT02388373 Comparator	Jul 2014 → Feb 2016	asthma	Research in Real-Life Ltd	Completed	No outcome recorded
Phase 4	NCT01751113 Comparator	Feb → Nov 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01555138 Comparator	Feb 2012 → Feb 2014	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01662778 Comparator	Dec 2011 → Dec 2012	asthma	Imperial College London	Completed	No outcome recorded
Phase 4	NCT01475721 Comparator	Nov 2011 → Jun 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01462344 Comparator	Nov 2011 → Nov 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01439815 Comparator	Sep → Oct 2011	allergic rhinitis, conjunctivitis	ORA, Inc.	Completed	No outcome recorded
Phase 4	NCT00845598 Comparator	Aug 2010 → Aug 2011	allergic rhinitis	University of Dundee	Withdrawn	No outcome recorded
Phase 4	NCT01192178 Comparator	Aug → Dec 2010	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01103934 Comparator	Jun 2010 → Jul 2011	seasonal allergic rhinitis	University of Chicago	Completed	No outcome recorded
Phase 4	NCT01110200 Comparator	Apr 2010 → Apr 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00995657 Comparator	Oct 2009 → Dec 2011	asthma	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01243788 Comparator	Jul 2009 → Feb 2011	chronic obstructive pulmonary disease	Fudan University	Unknown	No outcome recorded
Phase 4	NCT01526161 Background	Apr 2009 → Jun 2010	asthma	Professor Warren Lenney	Completed	No outcome recorded
Phase 4	NCT00857766 Comparator	Mar 2009 → Mar 2010	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00716963 Comparator	Jul → Nov 2008	intermittent asthma	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 4	NCT00691665 Comparator	May 2008 → Jan 2009	seasonal allergic rhinitis	Alcon Research	Completed	No outcome recorded
Phase 4	NCT00456313 Comparator	Dec 2007	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 4	NCT00503009 Comparator	Oct 2007 → Jul 2008	asthma	GlaxoSmithKline	Terminated	No outcome recorded
Phase 4	NCT00539006 Comparator	Aug → Nov 2007	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00519636 Comparator	Aug → Nov 2007	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00452699 Comparator	May 2007 → May 2009	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00452348 Comparator	May 2007 → Apr 2009	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00616538 Comparator	Dec 2006 → Apr 2007	atopic eczema	Ceragenix Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01388595 Comparator	Nov 2006 → Oct 2010	allergic rhinitis	University of Dundee	Completed	No outcome recorded
Phase 4	NCT00394355 Comparator	Sep 2006 → Oct 2009	asthma	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00250341 Comparator	Sep 2005 → Sep 2007	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 4	NCT00296491 Comparator	Sep 2005 → Oct 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00262587 Comparator	Sep 2005 → Dec 2008	asthma	Bispebjerg Hospital	Completed	No outcome recorded
Phase 4	NCT00351143 Background	Jul 2005 → Jun 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00119015 Comparator	Jul 2005 → Jun 2008	perennial allergic rhinitis	University of Chicago	Terminated	No outcome recorded
Phase 4	NCT00315744 Comparator	Nov 2004 → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00071552 Comparator	Jan 2004 → Jul 2006	asthma	Teva Branded Pharmaceutical Products R&D, Inc.	Terminated	No outcome recorded
Phase 4	NCT00118690 Background	Dec 2003 → Dec 2005	exercise-induced bronchoconstriction	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00920543 Comparator	Feb 2003 → Oct 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT01324362 Comparator	Jan 2003 → Oct 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded

Phase not applicable13 trials
—	NCT07537439 Background	Mar → Aug 2026 overdue	allergic rhinitis	University of Medicine and Pharmacy at Ho Chi Minh City	Active not recruiting	No outcome recorded
—	NCT07315555 Background	Jan → Jun 2026 overdue	—	Tanta University	Not yet recruiting	No outcome recorded
—	NCT07537751 Comparator	Feb → Dec 2024	atopic eczema	Noura Abdelmoneim Mohammed Elseessy	Completed	No outcome recorded
—	NCT02509299 Background	Sep → Nov 2019	chronic obstructive pulmonary disease	University of Granada	Completed	No outcome recorded
—	NCT04171167 Comparator	Apr 2017 → Dec 2025 overdue	chronic rhinosinusitis	Tampere University Hospital	Active not recruiting	No outcome recorded
—	NCT02883439 Comparator	Aug 2016 → Mar 2020	—	University Hospital, Ghent	Withdrawn	No outcome recorded
—	NCT02515318 Comparator	Sep 2015 → Mar 2017	chronic obstructive pulmonary disease	University of Granada	Unknown	No outcome recorded
—	NCT02748070 Background	Aug 2015 → Jul 2019	chronic rhinosinusitis	Stanford University	Completed	No outcome recorded
—	NCT02024204 Comparator	Apr 2014 → May 2017	lung disorder	NYU Langone Health	Completed	No outcome recorded
—	NCT01117116 Comparator	Mar 2010 → Sep 2013	asthma	National Jewish Health	Completed	No outcome recorded
—	NCT01184118 Comparator	Mar 2009 → Feb 2011	lung disorder	University of Wisconsin, Madison	Completed	No outcome recorded
—	NCT00706446 Background	Jun 2008 → Jun 2010	asthma	Brigham and Women's Hospital	Terminated	No outcome recorded
—	NCT00655616 Comparator	Aug 2007 → Aug 2009	asthma	University of Dundee	Completed	No outcome recorded

Press releases naming this drug 12 releases

Date	Issuer	Release
2020-09-21	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder tevapharm.com ↗
2020-02-24	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of ArmonAir® Digihaler™ (fluticasone propionate) Inhalation Powder tevapharm.com ↗
2019-07-15	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder tevapharm.com ↗
2017-11-27	Novartis Pharmaceuticals	Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide® novartis.com ↗
2017-06-15	Novartis Pharmaceuticals	FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus® novartis.com ↗
2017-04-20	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol tevapharm.com ↗
2016-09-03	Novartis Pharmaceuticals	Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups novartis.com ↗
2016-08-31	Novartis Pharmaceuticals	AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment novartis.com ↗
2016-06-28	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate RespiClick® Inhalers tevapharm.com ↗
2016-05-15	Novartis Pharmaceuticals	Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations novartis.com ↗
2015-11-19	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticasone Propionate Multidose Dry Powder Inhalers (MDPIs) in Patients with Asthma tevapharm.com ↗
2015-11-17	Novartis Pharmaceuticals	FLAME study shows superiority of Novartis' Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbations novartis.com ↗

Evidence & citations 39 cited values

Every value below carries the sentence it was read from. 347 sources stand behind the page.

Field	Value	Cited text
Known as	Fluticasone propionate	“Fluticasone propionate nasal spray (Fushuliang) combined with Azlastine hydrochloride tablets (Kedumin), Fluticasone propionate nasal spray (Fushuliang) 1 spray (50 µ g...” NCT07294326 ↗ 310 “A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment...” NCT00920543 ↗ “Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice...” NCT00562159 ↗ “PURPOSE: Using sputum neutrophils as the primary measure, and other inflammation biomarkers, this study evaluated the anti-inflammatory effects of the combination salmeterol 50...” PMID 25945045 ↗ Apr 2015 “BACKGROUND: This study tested the clinical non-inferiority of the fluticasone propionate/salmeterol combination 50/250 μg (FSC) Rotacaps®/Rotahaler® system, a single unit dose...” PMID 28115223 ↗ Jan 2017 “OBJECTIVE: We sought to investigate the efficacy and safety of the oral CRTH2 antagonist BI 671800 (50, 200, and 400 mg twice daily), fluticasone propionate nasal spray (200 μg...” PMID 24332218 ↗ Dec 2013 “Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled...” PMID 26006754 ↗ May 2015 “The purpose of this study is to optimise the device and/or formulation of the Fluticasone propionate (FP)/salmeterol (SALM) unit dose powder inhaler (Rotahaler) to achieve drug...” NCT01540708 ↗ “We randomly assigned 285 participants two or three years of age with a positive asthma predictive index to treatment with fluticasone propionate (at a dose of 88 mug twice...” PMID 16687711 ↗ May 2006 “Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total...” NCT00747318 ↗ “Fourteen subjects with moderate asthma inhaled single doses of salmeterol (50 μg), fluticasone propionate (250 μg), salmeterol/fluticasone propionate (50/250 μg), or placebo;...” PMID 21980058 ↗ Oct 2011 “Recent concerns have been expressed about the safety of ICS in COPD following several randomised controlled trials of fluticasone propionate and fluticasone furoate, among...” NCT02972476 ↗ “compare Systemic Exposure and Pharmacodynamics of Fluticasone Propionate and Salmeterol Following Advair HFA 45/21mcg (2 Inhalations), ADVAIR® HFA 45/21mcg (2 Inhalations) With...” NCT00400608 ↗ “The combination of salmeterol and fluticasone propionate (SFC) and tiotropium bromide (TIO) are commonly used treatments in chronic obstructive pulmonary disease (COPD) but...” PMID 18245142 ↗ Feb 2008 “ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID)...” NCT01192178 ↗ “OBJECTIVE: Characterize fluticasone propionate (Fp) and combination fluticasone propionate and salmeterol (FS) pharmacokinetic and safety profiles, delivered via a novel,...” PMID 28933971 ↗ Oct 2017 “A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate)...” NCT02609126 ↗ “For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6...” NCT04655508 ↗ “A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and...” PMID 31732149 ↗ Nov 2019 “FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and...” NCT02141854 ↗ “Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in...” PMID 27599598 ↗ Sep 2016 “This study evaluates 10 mg/d montelukast and 250 μg of fluticasone propionate twice daily, each compared with placebo, in patients with self-reported active smoking (unable to...” PMID 23380218 ↗ Feb 2013 “SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations...” NCT00657774 ↗ “Low-dose inhaled corticosteroid (fluticasone propionate 200 µg/day) combined with a long-acting beta-2 agonist (two puffs every 12 hours), administered via metered-dose inhaler...” NCT07315555 ↗ “Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir.” NCT01576718 ↗ “Fluticasone Propionate / Formoterol Fumarate (Flutiform®) 250/10 µg (2 Puffs BID) and Flutiform® 125/5 µg (2 Puffs BID) Versus Formoterol Fumarate Dihydrate (Atimos®) 12 µg (1 Puff BID)” NCT01946620 ↗ “Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir.” NCT01479621 ↗ “Salmeterol 50 mcg /fluticasone propionate 500 mcg for inhalation delivered via a proprietary multi dose dry powder inhaler (MDDPI) device (Seretide® Accuhaler®) twice daily (b.i.d.)” NCT01555138 ↗ “Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir.” NCT01772368 ↗ “Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir.” NCT02139644 ↗ “Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks.” NCT03169504 ↗ “Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.” NCT02509299 ↗ “This study will form the next step in the investigation of this commonly used inhaled steroid Fluticasone Propionate, used in asthma, bronchitis and emphysema patients.” NCT01662778 ↗ “AFC is a fixed-dose combination product of Azelastine hydrochloride (137mcg), a selective H1-receptor antagonist and, Fluticasone propionate (50mcg), a corticosteroid.” NCT06051786 ↗ “Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.” NCT02175771 ↗ “SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation.” NCT00649025 ↗ “Treat with intranasal Azelastine and Fluticasone Propionate and re-evaluate ARCT score to assure ARCT≥20 after 2 weeks, before randomization.” NCT05080322 ↗ “Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide” NCT02515318 ↗ “asthma subjects were randomized to MF/F 200/10 μg, MF/F 400/10 μg, fluticasone propionate/salmeterol (FP/S) 250/50 μg, and FP/S 500/50 μg.” PMID 25044280 ↗ May 2014 “Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate” NCT01388595 ↗ “The Impact of an Anti-static Valved-holding Chamber on Bioavailability of Inhaled Fluticasone Propionate in Young Children With Asthma” NCT00307970 ↗ “intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).” NCT00903227 ↗ “fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation.” PMID 25248764 ↗ Sep 2014 “The overall hypothesis of this study is to determine whether inhaled fluticasone propionate (FP) increases UAW collapsibility” NCT01184118 ↗ “Fluticasone propionate and Salmeterol delivered in a capsule-based inhaler versus a multi-dose dry powder inhaler” NCT01494610 ↗ “A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis.” PMID 26108088 ↗ Jul 2015 “Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education” NCT03110874 ↗ “APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.” NCT05634746 ↗ “Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks” NCT00783224 ↗ “APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.” NCT05083312 ↗ “Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks” NCT00071552 ↗ “Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®” NCT02571777 ↗ “250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate.” NCT02388373 ↗ “Patients were treated with fluticasone propionate (500 μg bid) or placebo for 2.5 years.” PMID 26659582 ↗ Dec 2015 “Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation” NCT02113436 ↗ “Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation” NCT03524066 ↗ “addition of a LABA (salmeterol) to an inhaled glucocorticoid (fluticasone propionate)” PMID 31553835 ↗ Sep 2019 “Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device” NCT00655616 ↗ “to receive fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks.” PMID 27579634 ↗ Sep 2016 “OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID” NCT06850805 ↗ “fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination” NCT06290102 ↗ “Participants either receive fluticasone propionate or mometasone furoate.” NCT05545072 ↗ “Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder” NCT03562923 ↗ “fixed-dose fluticasone propionate/salmeterol 250/50 microg twice daily” PMID 20170333 ↗ Mar 2010 “Fluticasone Propionate / Salmeterol administered using CRC749 inhaler” NCT02474017 ↗ “a combination of salmeterol 50 μg plus fluticasone propionate 500 μg” PMID 28982774 ↗ Oct 2017 “Fluticasone Propionate/Salbutamol Sulfate. Oral inhalation powder.” NCT06052267 ↗ “Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks” NCT01908140 ↗ “fluticasone propionate (100) twice daily (AM and PM) for 6 months” NCT01475721 ↗ “salmeterol/fluticasone propionate (SAL/FP) 50/500 µg twice daily” PMID 25841237 ↗ Apr 2015 “fluticasone propionate/salmeterol (FP/SAL, branded) 500/50 mcg” PMID 27334739 ↗ Jun 2016 “HFA-Fluticasone Propionate (FP) in children of different ages” NCT00308932 ↗ “fluticasone propionate at a dose of 44 μg per inhalation” PMID 29504498 ↗ Mar 2018 “Fluticasone propionate nasal spray 200 μg/d for 3 months” NCT02182492 ↗ “Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID” NCT00857766 ↗ “fluticasone propionate/albuterol sulfate combination” NCT06664619 ↗ “twice-daily fluticasone propionate (FP) 500 mcg” PMID 25524507 ↗ Oct 2014 “Fluticasone propionate/salmeterol combination” NCT00920959 ↗ “Fluticasone propionate 400 microgram daily” NCT01657097 ↗ “200mcg Fluticasone Propionate Nasal Spray” NCT00519636 ↗ “Fluticasone Propionate DISKUS Twice Daily” NCT01324362 ↗ “Fluticasone propionate (FP),Azithromycin” NCT04527016 ↗ “Fluticasone propionate 250 mcg BID” NCT00452699 ↗ “fluticasone propionate nasal spray” NCT00539006 ↗ “Fluticasone Propionate 100 mcg BD” NCT00517634 ↗ “fluticasone propionate (FP)” PMID 24010736 ↗ Sep 2013 “fluticasone propionate” NCT00539006 ↗ “Fluticasone Propionate” NCT01424397 ↗ NCT02024204 ↗ NCT01159912 ↗ NCT00400855 ↗ NCT01554488 ↗ NCT01624662 ↗ NCT05275686 ↗ NCT00651118 ↗ NCT07582549 ↗ NCT00448435 ↗ NCT02402465 ↗ NCT03594565 ↗ NCT04179461 ↗ NCT01794741 ↗ NCT02523820 ↗ NCT02680561 ↗ NCT00115492 ↗ NCT02991859 ↗ NCT01253603 ↗ NCT04601324 ↗ NCT00712335 ↗ NCT01134042 ↗ NCT01064726 ↗ NCT00716963 ↗ NCT00479739 ↗ NCT02883439 ↗ NCT03207243 ↗ NCT07324707 ↗ NCT00407264 ↗ NCT00848965 ↗ NCT02246920 ↗ NCT00656916 ↗ NCT00395304 ↗ NCT01243788 ↗ NCT00370097 ↗ NCT00877539 ↗ NCT05363202 ↗ NCT00169546 ↗ NCT02136875 ↗ NCT01092143 ↗ NCT00355342 ↗ NCT01623310 ↗ NCT07537751 ↗ NCT07537439 ↗ NCT03756883 ↗ NCT02230696 ↗ NCT00612820 ↗ NCT01449799 ↗ NCT01817764 ↗ NCT00540839 ↗ NCT03394989 ↗ NCT02338362 ↗ NCT00348361 ↗ NCT00358358 ↗ NCT00633217 ↗ NCT02094937 ↗ NCT01323634 ↗ NCT00846326 ↗ NCT01915914 ↗ NCT00461500 ↗ NCT01573767 ↗ NCT01397201 ↗ NCT00280358 ↗ NCT02740543 ↗ NCT00269126 ↗ NCT03112577 ↗ NCT00503009 ↗ NCT01564199 ↗ NCT00394121 ↗ NCT00400998 ↗ NCT00774761 ↗ NCT01147744 ↗ NCT00393991 ↗ NCT03926026 ↗ NCT01397162 ↗ NCT00449046 ↗ NCT01365611 ↗ NCT02218762 ↗ NCT00755066 ↗ NCT00197106 ↗ NCT01117116 ↗ NCT01890863 ↗ NCT00734292 ↗ NCT02573233 ↗ NCT00364442 ↗ NCT01147848 ↗ NCT00296491 ↗ NCT02141633 ↗ NCT01751113 ↗ NCT01436110 ↗ NCT01400906 ↗ NCT01622569 ↗ NCT01439815 ↗ NCT01687296 ↗ NCT01124422 ↗ NCT01623323 ↗ NCT00830102 ↗ NCT00404586 ↗ NCT00691665 ↗ NCT01687283 ↗ NCT01435902 ↗ NCT06858423 ↗ NCT02249663 ↗ NCT00424008 ↗ NCT00296530 ↗ NCT05314621 ↗ NCT02496715 ↗ NCT00927758 ↗ NCT00393952 ↗ NCT00102765 ↗ NCT01396278 ↗ NCT00706446 ↗ NCT00995800 ↗ NCT01845025 ↗ NCT00346749 ↗ NCT00453778 ↗ NCT01168310 ↗ NCT01817790 ↗ NCT00411372 ↗ NCT00102882 ↗ NCT00394368 ↗ NCT00441441 ↗ NCT01260753 ↗ NCT01103934 ↗ NCT02232087 ↗ NCT02730351 ↗ NCT00616538 ↗ NCT00370591 ↗ NCT00975195 ↗ NCT00995657 ↗ NCT00487032 ↗ NCT00995475 ↗ NCT03742414 ↗ NCT07664527 ↗ NCT02290717 ↗ NCT01400568 ↗ NCT00351143 ↗ NCT00394199 ↗ NCT01772147 ↗ NCT00184977 ↗ NCT03055988 ↗ NCT00398476 ↗ NCT00315744 ↗ NCT02446418 ↗ NCT00549146 ↗ NCT04677959 ↗ NCT03882047 ↗ NCT01772134 ↗ NCT00452699 ↗ NCT07675252 ↗ NCT00641680 ↗ NCT04953741 ↗ NCT03879837 ↗ NCT00845598 ↗ NCT00843193 ↗ NCT04957927 ↗ NCT00361959 ↗ NCT02301975 ↗ NCT01762800 ↗ NCT03199976 ↗ NCT03040596 ↗ NCT00268216 ↗ NCT00239421 ↗ NCT01563029 ↗ NCT00814216 ↗ NCT00546000 ↗ NCT01966692 ↗ NCT00740792 ↗ NCT04665895 ↗ NCT02260492 ↗ NCT01712451 ↗ NCT00489346 ↗ NCT00144911 ↗ NCT03676413 ↗ NCT01578278 ↗ NCT07415278 ↗ NCT03240575 ↗ NCT00118690 ↗ NCT00118716 ↗ NCT01706328 ↗ NCT00394355 ↗ NCT00291382 ↗ NCT04242368 ↗ NCT05535738 ↗ NCT00452348 ↗ NCT00403286 ↗ NCT00883168 ↗ NCT04171167 ↗ NCT02245672 ↗ NCT00266578 ↗ NCT00158834 ↗ NCT00475813 ↗ NCT01516086 ↗ NCT05054322 ↗ NCT00268177 ↗ NCT03591068 ↗ NCT01307462 ↗ NCT01364519 ↗ NCT00984659 ↗ NCT00660517 ↗ NCT00119015 ↗ NCT03443843 ↗ NCT00869596 ↗ NCT00353873 ↗ NCT01018186 ↗ NCT00784550 ↗ NCT04332978 ↗ NCT05444543 ↗ NCT00318708 ↗ NCT02980133 ↗ NCT02554786 ↗ NCT01822899 ↗ NCT02610816 ↗ NCT01969721 ↗ NCT00241631 ↗ NCT01606306 ↗ NCT00328718 ↗ NCT03599791 ↗ NCT00692978 ↗ NCT01323621 ↗ NCT02476825 ↗ NCT01526161 ↗ NCT02778867 ↗ NCT01516073 ↗
Known as	Advair	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02826343 ↗ 2 NCT00250341 ↗ NCT00461812 ↗
Known as	Advair Diskus	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00385463 ↗ 4 NCT00974246 ↗ NCT03219866 ↗ NCT02251379 ↗ NCT03676413 ↗
Known as	APT-1011	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03191864 ↗ 2 NCT05095116 ↗ NCT04281108 ↗
Known as	Cutivate	“using Cutivate (fluticasone propionate, 0.05%)lotion” NCT00546000 ↗
Known as	EDS-FLU	“A new exhalational delivery system fluticasone spray (EDS-FLU) has been FDA-approved for patients with chronic rhinosinusitis with polyps.” NCT05275686 ↗
Known as	EP-104IAR	“A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate)...” NCT02609126 ↗
Known as	FF	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02924688 ↗
Known as	Flixonase	“Children whose parents had difficulty with CGMS due to irritation, redness were offered to use Flixonase (FLUTICASONE PROPIONATE), with an approval form 29ג, indicating it is...” NCT03594565 ↗ 2 “intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).” NCT00903227 ↗ “Fluticasone Propionate - FLIXONASE® brand” NCT04332978 ↗
Known as	Flixotide	“The clinical trial is to investigate the pharmacokinetic effects (that is how much drug is in the blood) of Fluticasone Propionate (Flixotide), a commonly used steroid drug...” NCT00692978 ↗ 11 “These patients will never have been prescribed the components present in Seretide (Salmeterol and Flixotide or similar compounds).” NCT00974805 ↗ “Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device” NCT00655616 ↗ “Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily” NCT00353873 ↗ “FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)” NCT00453778 ↗ “100 mcg Flixotide (FP only) via Diskus inhaler” NCT00455923 ↗ “and/or Fluticasone Propionate (Flixotide®)” NCT00158834 ↗ NCT01511367 ↗ NCT01738087 ↗ NCT00456313 ↗ NCT00455923 ↗ NCT00734318 ↗
Known as	Flixotide Evohaler	“Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate” NCT01388595 ↗ 2 “Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)” NCT00830102 ↗ “Fluticasone propionate 125 micrograms (Trade name: Flixotide Evohaler)” NCT07582549 ↗
Known as	Flonase	“Xhance®, Flonase® (fluticasone propionate inhalational nasal spray), and Flovent® HFA (fluticasone propionate inhalational aerosol).” PMID 31732149 ↗ Nov 2019 4 “Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days” NCT02246920 ↗ “Nasal Steroid (Nasonex, Flonase)” NCT02874144 ↗ NCT02748070 ↗ NCT02569437 ↗
Known as	Flonase Allergy Relief	“Flonase® Allergy Relief (fluticasone propionate) will be administered nasally (within 5 minutes of eyedrop) at Visits 3 and 4a.” NCT05314621 ↗
Known as	FLOVENT	“A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice...” NCT00452348 ↗ 4 “Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID” NCT00452699 ↗ “maintenance inhaled corticosteroid (Flovent)” NCT05689983 ↗ “FLOVENT (fluticasone propionate) HFA” NCT00370097 ↗ NCT00426283 ↗
Known as	Flovent Diskus	“Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose...” NCT01479621 ↗ 3 “Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks” NCT00071552 ↗ “Fluticasone propionate (Flovent Diskus) 250 mcg” NCT00716963 ↗ NCT02251379 ↗
Known as	Flovent HFA	“Flovent® HFA (fluticasone propionate) inhalational aerosol” PMID 31732149 ↗ Nov 2019 1 NCT02266927 ↗
Known as	fluticason propionate	“inhaled corticosteroid (fluticason propionate)” NCT00184977 ↗
Known as	fluticasone	“This study investigated the efficacy and tolerability of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol)*, administered...” PMID 23870606 ↗ Jul 2013 4 “combination spray of azelastine and fluticasone (antihistamine and steroid) compares with a steroid nasal spray (fluticasone) alone in allergic rhinitis” NCT00845598 ↗ “The authors did use fluticasone propionate and salmeterol (either the combination or fluticasone alone), which is marketed by GlaxoSmithKline.” PMID 23667615 ↗ May 2013 “in a 16-week observational inhaled fluticasone (FP) treatment study” NCT01554488 ↗ “Fluticasone is an inhaled corticosteroid” NCT02066129 ↗
Known as	Fluticasone Evohaler	“One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)” NCT00903227 ↗
Known as	Fluticasone Evohaler pMDI	“One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)” NCT00903227 ↗
Known as	Fluticasone propionate (generic name)	“Fluticasone propionate (generic name)” NCT02246920 ↗
Known as	Fluticasone propionate BP	“Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination” NCT00845598 ↗
Known as	fluticasone propionate nasal spray	“fluticasone propionate nasal spray” NCT00539006 ↗
Known as	Fluticasone Propionate Powder for Inhalation (Seretide)	“Fluticasone Propionate Powder for Inhalation (Seretide®)” NCT03169504 ↗
Known as	Fp MDPI	“Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir.” NCT01479621 ↗
Known as	FP500	“Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with...” NCT00358358 ↗
Known as	FPANS	“Intranasal FPANS (Fluticasone Propionate aqueous nasal spray)” NCT00400998 ↗
Known as	FPNS	“OBJECTIVE: To compare fluticasone propionate nasal spray (FPNS) with the second-generation antihistamine cetirizine (oral tablet) and with placebo in a head-to-head study in a...” PMID 26108088 ↗ Jul 2015 1 NCT00519636 ↗
Known as	FSC	“Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID” NCT00385463 ↗
Known as	Fushuliang	“Fluticasone propionate nasal spray (Fushuliang) combined with Azlastine hydrochloride tablets (Kedumin), Fluticasone propionate nasal spray (Fushuliang) 1 spray (50 µ g...” NCT07294326 ↗
Known as	NCX 4251	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04675242 ↗
Known as	OPN-375	“OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID” NCT06850805 ↗
Known as	PF-00241939	“The purpose of this study is to investigate the time course of PF-00241939 concentration in the blood following dosing by oral inhalation from dry powder inhalers.” NCT00862667 ↗ 2 “PF-00241939 300 ug using inhaler A” NCT01181700 ↗ “PF-00241939 750ug using inhaler A” NCT00867282 ↗
Known as	PLURAIR	“Drug names: Fluticasone Propionate - PLURAIR® brand” NCT04332978 ↗
Known as	Seretide	“Seretide disc 100-250-500 mcg/dosage 60 dosage” NCT00628758 ↗ 7 NCT00262587 ↗ NCT01647646 ↗ NCT02813200 ↗ NCT01274325 ↗ NCT03461627 ↗ NCT03468790 ↗ NCT00642148 ↗
Known as	Xhance	“This study will compare placebo to fluticasone exhalational nasal spray system (Xhance) in a randomized, controlled study.” NCT05275686 ↗
Action	Activate	“This glucocorticoid is characterized by high lipophilicity, high glucocorticoid receptor binding and activation, and a rapid metabolic turnover in skin.” NCT03594565 ↗
Modality	Other / unclassified	“use of the inhaled corticosteroid” PMID 16687711 ↗ May 2006
Route	Inhaled	“Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler)” NCT00071552 ↗